Alnylam Pharmaceuticals is under pressure as its stock continues to decline amid concerns about its valuation and ongoing legal issues.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) saw its stock price drop by 1.54%, closing at CA$223.52. This decline comes as the company faces increasing scrutiny over its financial outlook and ongoing legal challenges.
Investor takeaway: Investors should be cautious since Alnylam's valuation remains high compared to its earnings potential, especially with recent legal troubles that raise questions about the company's future profitability.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$31.13B
P/E
39.2x
52W high
$495.55
52W low
$197.81
1W change
+3.24%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 12, 2026
Wall Street analysts forecast ALNY stock price to rise 63.2% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$370.55
+63.2% Upside
Previously C$371.12 on Oct 5, 2026
Current Price
C$227.02
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
47.6%
Annualized
90-Day Vol
70.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$189.89
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$213.90 | C$181.52 – C$252.05 |
| 60 trading days | C$201.54 | C$159.79 – C$254.19 |
| 90 trading days | C$189.89 | C$142.91 – C$252.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Alnylam has a strong pipeline with over 25 programs in development. If these programs succeed, they could offer significant growth opportunities for the company.
Bear case
However, ongoing legal scrutiny and a sharp decline in earnings estimates cast doubt on Alnylam's ability to meet its growth projections, suggesting that the current stock price may be overvalued.
Valuation Concerns Weigh on Alnylam
Advertisement
Alnylam's stock has dropped 43.5% this year, raising concerns about its valuation amid ongoing legal scrutiny. Analysts point out that despite a promising pipeline, the current P/E ratio of 37.34 is much higher than the industry average, indicating that investors might be overpaying for future growth potential.
Legal Challenges Add Uncertainty
The company is currently facing a securities fraud investigation, complicating its financial outlook. This scrutiny comes at a time when sales expectations for its TTR franchise have been sharply reduced, leading to increased skepticism about Alnylam's ability to meet its earnings projections.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
